The cardiometabolic syndrome is a concept recently developed by the American Heart Association to denote the totality of risk in a patient with risk factors that may lead to or worsen chronic kidney disease or cardiovascular events. A new validated scoring system has been endorsed by AHA to better assess the short and long-term risk for these in the general population. We will discuss this scoring system in this podcast.

THE GAMECHANGER: A new validated scoring system has incorporated factors to better determine the 10 and 30 year risk of CVD and CKD in a general population.

Upon successful completion of this course, learners should be able to:
1. Describe the concept of the Cardiovascular-Kidney-Metabolic syndrome.
2. Discuss how the PREVENT scoring system is applied to patients.

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Mathew Boyd, PharmD
Clinical Pharmacist
Unity Point

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Matthew Boyd has no relevant financial relationships with ineligible companies to disclose. 

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: March 4, 2024
Planned Expiration Date: March 4, 2025

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.